Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Teva Pharmaceutical (TEVA)

Tipranks - Tipranks - Fri Apr 10, 9:40AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InflaRx (IFRX) and Teva Pharmaceutical (TEVA) with bullish sentiments.

Easter Sale - 70% Off TipRanks

InflaRx (IFRX)

In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on InflaRx, with a price target of $6.00. The company’s shares closed last Thursday at $1.01.

According to TipRanks.com, Keller is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -27.1% and a 22.2% success rate. Keller covers the Healthcare sector, focusing on stocks such as 60 Degrees Pharmaceuticals, Inc., Acurx Pharmaceuticals, and Galectin Therapeutics. ;'>

InflaRx has an analyst consensus of Strong Buy, with a price target consensus of $7.33, which is a 657.7% upside from current levels. In a report issued on March 31, Guggenheim also maintained a Buy rating on the stock with a $14.00 price target.

See the top stocks recommended by analysts >>

Teva Pharmaceutical (TEVA)

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Teva Pharmaceutical today. The company’s shares closed last Thursday at $30.40.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 16.0% and a 61.1% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Mineralys Therapeutics, Inc., and Amylyx Pharmaceuticals Inc. ;'>

Currently, the analyst consensus on Teva Pharmaceutical is a Strong Buy with an average price target of $39.57, which is a 30.0% upside from current levels. In a report issued on March 25, TipRanks – PerPlexity also upgraded the stock to Buy with a $32.00 price target.

Read More on IFRX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).